On February 5, Haisike (002653) issued an announcement that its subsidiaries Tibet Haisike Pharmaceutical Co., Ltd. and Sichuan Haisike Pharmaceutical Co., Ltd. recently received the "Notice of Approval for Drug Clinical Trials" issued by the State Drug Administration, approving the innovative drug HSK39004 inhalation powder spray developed by them to conduct clinical trials. The drug is mainly used to treat chronic obstructive pulmonary disease and meets the relevant requirements for drug registration.

HSK39004 is a targeted small molecule inhibitor independently developed by the company. Preclinical studies have shown that it has significant effects on airway relaxation and anti-inflammation, and has good safety and great development potential. According to the drug registration classification regulations, the drug is classified as Class 1 chemical drug. Although the project has good prospects, the company also reminds investors that the research and development cycle of innovative drugs is long and the risk is high, and careful decision-making is required.

In the first three quarters of 2024, Hiseco achieved revenue of 2.751 billion yuan and net profit attributable to shareholders of the parent company of 382 million yuan.

https://finance.eastmoney.com/a/202502053311277329.html